Efficacy data were computed from all randomized trials (RT) that guided on-label uses of bevacizumab (K-Ras mutated), panitumumab and cetuximab. Non-significant outcomes and toxicity as predictor of efficacy were excluded. Prices for drugs in Spain were assumed to represent the best-value for each drug including all possibilities to reduce pharmacy costs. For 1st line, median duration of therapy reported by RT was used to calculate the final budget. 70kg and 1.7 m were used as reference for patient dose calculations. RESULTS: We simulated 3 main scenarios based on the possibilities of therapy for K-Ras wild type (wt) patients assuming that all patients harboring a K-Ras mutated tumor received bevacizumab based chemotherapy. So, in scenario A K-Ras wt patients received weekly cetuximab combined with FOLFOX, ORR reaches 54% and global cost per RR sums €20,026. Scenario B: administering panitumumab-FOLFOX yields 51% ORR and € 19,861 per RR. Scenario C: cetuximab biweekly combined with FOLFOX yields 54% and €19,726. ICER for scenario A vs B is estimated at € 22,835 per additional response. ICER for scenario C vs B is estimated at € 968 per additional response. CONCLUSIONS: First-line oxalipatin combinations of cetuximab for wt and bevacizumab for mutated patients optimize response rate rather than panitumumab and bevacizumab schedules. Efficiency of this therapeutic approach could be improved with biweekly cetuximab administration. Marginal cost differences between cetuximab and panitumumab therapies are exceeded by efficacy gap as measured by response rates in RT. 
PCN73 ECONOMIC ANALYSIS OF THE USE OF CRIZOTINIB, A TYROSINE KINASE ALK INHIBITOR, IN THE TREATMENT OF ALK POSITIVE NON-SMALL CELL LUNG CANCER IN THE MEXICAN SETTING
Tecnología e Informática para la Salud, S.A. de C.V., Mexico City, Distrito Federal, Mexico, 2 Tecnología e Informática para la Salud, S.A. de C.V., Mexico City, Mexico, 3 Pfizer S. A. de C.V., Mexico City, Mexico OBJECTIVES: Crizotinib, a tyrosine kinase anaplastic lymphoma kinase (ALK) inhibitor, represents a therapeutic alternative to patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that are ALKϩ. This study aimed to estimate the cost-effectiveness of crizotinib in the treatment of this group of patients compared to currently available chemotherapy schemes: gemcitabineϩcisplatin (GC), pemetrexedϩcisplatin (PC) and docetaxelϩcisplatin (DC), from the Mexican public payer's perspective. METHODS: A mutually exclusive, four-state Markov model was developed: stable without progression, stable with response to treatment, disease progression and death (monthly transitions, six-year timeframe, 5% discount rate). The model assess life-years gained and direct medical costs (pre-treatment, drugs costs, drug administration, monitoring and adverse event management), per each treatment (basecase GC), in terms of ICER. Effectiveness data was extracted from published literature. Drug costs and medical resources were extracted from Instituto Mexicano del Seguro Social database. Crizotinib's cost were provided by manufacturer (not listed yet in Mexican formulary) and are expressed in 2012 US$. Univariate sensitivity analyses regarding monthly acquisition cost and clinical efficacy of crizotinib were performed. RESULTS: Crizotinib was the most effective alternative with 3.02 life-years gained, compared with 1.55, 1.74 and 1.34 for GC, PC and DC, respectively. The cost of GC was $15,792.3, while the incremental cost for PC, DC and crizotinib were $10,787.4, $13,171 and $61,895.3, respectively. DC was dominated, while ICER for PC and crizotinib were $56,775.9 and $42,105.6, respectively, being crizotinib a cost-effective alternative. Results were sensible to changes in acquisition cost of crizotinib and less sensible to changes in the probabilities of death and disease progression with crizotinib. CONCLUSIONS: From the Mexican public payer's perspective, crizotinib would represent an opportunity for both, this group of patients, and health care institutions to achieve better clinical results than GC, PC and DC, as well as minor cost regarding PC.
PCN74 COST EFFECTIVENESS OF CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF BREAST CANCER IN EUROPE: A MULTI-COUNTRY STUDY
Walter E, Mercsanits D Institute for Pharmaeconomic Research, Vienna, Austria OBJECTIVES: Breast-cancer is the most frequent malignancy amongst women in Europe and therefore represents a major public-health problem. The purpose of this analysis was to estimate the cost-effectiveness of AT (doxorubicin, docetaxel) compared with AC (doxorubicin, cyclophosphamide), CMF (cyclophosphamide, methotrexat, 5-fluoruracil) and FEC (5-fluoruracil, epirubicin, cyclophosphamide) administered as adjuvant therapy to women with node-positive breast-cancer across four European countries (Spain, Italy, Germany and Belgium). METHODS: We developed a multi-country Markov-model to simulate the long-term consequences from initiation of adjuvant chemotherapy over 10 years. The model simulates the incidence of complications during chemotherapy (febrile neutropenia, chemotherapy-induced nausea/vomiting, dose-reduction, dose-delay, grade 3/4 adverse events) and long-term consequences like local or distant-relapse, acute myelogenous leukemia (AML), chronic heart failure and death. Monte-Carlo-simulation accounted for uncertainty. The model includes twelve health-states. Probabilities were derived from clinical and epidemiological studies; direct costs (2011) from published sources from the payer's perspective. QALYs, life-years (LYs) and costs were discounted at 5% p.a. RESULTS: Over a 10-year timeframe, costs associated with AC are 13,266€, 14,826€, 15,699€ and 16,558€ for Spain, Italy, Germany and Belgium, respectively. AC is associated with 5.85 QALYs (6.49 LYs). Costs for AT amount to 15,362€ (Spain), 19,004€ (Italy), 19,768€ (Germany) and 20,625€ (Belgium) and AT delivers a similar benefit to AC: 5.85 QALYs (6.50 LYs). The resulting opportunities for cost-savings with AC vs. AT are between 2,096€ (Spain) and 4,178€ (Italy). Costs associated with CMF are 14,145€ (Spain), 15,609€ (Italy), 16,411€ (Germany) and 16,924€ (Belgium); 5.8 QALYs (6.4 LYs) are gained. AC dominates CMF. FEC associated total costs are 15,138€ (Spain), 15,652€ (Italy), 17,431€ (Germany) and 17,492€ (Belgium). QALYs are 6.03 (6.81 LYs). FEC dominates AT in all four countries. CONCLUSIONS: Cyclophosphamide-based regimens (FEC, AC and CMF) demonstrate a better performance from cost-effectiveness perspective vs. AT in the four European countries. 
PCN75 SURVIVAL AND COSTS IN METASTATIC RENAL CELL CARCINOMA: A COMPARISON OF MRCC TREATMENT PRE-AND POST TYROSINE KINASE INHIBITOR (TKI) INTRODUCTION USING RETROSPECTIVE REGISTRY DATA

OBJECTIVES:
Renal cell carcinoma (RCC) accounts for approximately 2% of all cancers worldwide. Many patients present with advanced or unresectable disease, and up to 30% of patients treated by nephrectomy for localized disease will relapse. Improved care for patients with metastatic RCC (mRCC), including targeted therapies have improved prognosis but have also increased drug costs. In this study, we set out to study costs and outcomes in mRCC treatment using national registries comprising all patients diagnosed with RCC in Sweden. METHODS: Two cohorts of patients diagnosed with mRCC 2002-2005 and 2006-2008 , representing patients diagnosed pre-and post-TKI introduction respectively, were identified in the national Swedish Cancer Registry. A pre-defined algorithm was used to determine the presence of mRCC. Through record linkage with the national registries for drug prescriptions, hospital care, and causes of death, data on resource utilization and survival was obtained. The Kaplan-Meier method was used to estimate survival, using an exponential model to calculate the mean for 4.5 years -beyond the end of the observation period. Costs were estimated in 2010 SEK (1 SEK ϭ USD ($) 0.14), using the Lin method to account for censoring. Sensitivity analysis was done to better incorporate the cost of hospital dispensed drugs. RESULTS: Patients diagnosed post-TKI introduction (nϭ1,217) had longer survival (median 1.08 compared to 0.79 years, restricted mean 1.73 compared to 1.55, both p Ͻ 0.001) compared to patients diagnosed pre-TKI introduction (nϭ1,536). Costs were higher for patients more recently diagnosed: $52,601 versus $40,970. Pharmaceutical costs were $12,418 higher in the post period but where slightly offset by lower inpatient care costs. The cost per life-year gained (LYG) amounted to $64,616. CONCLUSIONS: The study suggests that mRCC survival has improved in recent years while costs have increased, resulting in a fairly modest cost per LYG in a Swedish setting. 
PCN76 COST-EFFECTIVENESS OF ERLOTINIB AS FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL-CELL LUNG CARCINOMA IN PATIENTS EGFR WT AND STABLE DISEASE AFTER FOUR CYCLES OF CHEMOTHERAPY
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